Elsevier, hLife, Volume 2, August 2024
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated disease characterized by refractory and relapsed peripheral nerve and nerve root damage, leading to severe sequelae for patients. Although glucocorticoids, intravenous immunoglobulin (IVIg), and immunosuppressive agents are recommended for treating CIDP and preventing relapses, some patients’ conditions cannot be effectively controlled. Due to the uncertain efficacy and toxicity issues of broad-spectrum immune-modulatory or suppressive drugs, developing a safe and effective treatment strategy is warranted.
